1. Catalog
  2. Nodes
  3. path(MESH:"Attention Deficit Disorder with Hyperactivity")

path(MESH:"Attention Deficit Disorder with Hyperactivity")

Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
Attention Deficit Disorder with Hyperactivity
Namespace
mesh
Namespace Version
20181007
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns

Appears in Networks 2

Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system v1.0.0

This document contains the curation of the review article Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system by Taly et al. 2009

Clinical presentation of a complex neurodevelopmental disorder caused by mutations in ADNP v1.0.0

In-Edges 3

a(MESH:"3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole") association path(MESH:"Attention Deficit Disorder with Hyperactivity") View Subject | View Object

ABT-418, discussed above, has also been found to be active in a limited human trial in attention deficit hyperactivity disorder (ADHD)171. A second compound, ABT-089, which is a partial agonist at alpha4beta2 nAChRs, was also efficacious in ADHD172 PubMed:19721446

Appears in Networks:
Annotations
Text Location
Review

a(MESH:pozanicline) association path(MESH:"Attention Deficit Disorder with Hyperactivity") View Subject | View Object

ABT-418, discussed above, has also been found to be active in a limited human trial in attention deficit hyperactivity disorder (ADHD)171. A second compound, ABT-089, which is a partial agonist at alpha4beta2 nAChRs, was also efficacious in ADHD172 PubMed:19721446

Appears in Networks:
Annotations
Text Location
Review

p(HGNC:ADNP) decreases path(MESH:"Attention Deficit Disorder with Hyperactivity") View Subject | View Object

Forty-four percent of the individuals are hyperactive or easily distracted. About one third of them have a diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). PubMed:29724491

Appears in Networks:

Out-Edges 2

path(MESH:"Attention Deficit Disorder with Hyperactivity") association a(MESH:"3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole") View Subject | View Object

ABT-418, discussed above, has also been found to be active in a limited human trial in attention deficit hyperactivity disorder (ADHD)171. A second compound, ABT-089, which is a partial agonist at alpha4beta2 nAChRs, was also efficacious in ADHD172 PubMed:19721446

Appears in Networks:
Annotations
Text Location
Review

path(MESH:"Attention Deficit Disorder with Hyperactivity") association a(MESH:pozanicline) View Subject | View Object

ABT-418, discussed above, has also been found to be active in a limited human trial in attention deficit hyperactivity disorder (ADHD)171. A second compound, ABT-089, which is a partial agonist at alpha4beta2 nAChRs, was also efficacious in ADHD172 PubMed:19721446

Appears in Networks:
Annotations
Text Location
Review

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.